The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | How can infusion-related reactions from amivantamab be reduced in the clinic?
Gilberto Lopes, MD, University of Miami, Miami, FL, discusses strategies to reduce infusion-related reactions from amivantamab that can be applied in the clinic for non-small cell lung cancer (NSCLC). Findings from the Phase II SKIPPirr study (NCT05663866) have demonstrated the efficacy of prophylactic dexamethasone two days before infusion of amivantamab in terms of reducing infusion-related reactions. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
